CANNAPHARMARX, INC. (CPMD) Form 10-Q — May 20, 2026
CannaPharmaRx reported a net loss of $382,021 for the quarter ended March 31, 2026, driven by a gross loss of $409,453 despite revenue growth to $627,462. The company holds only $633 in cash and disclosed a working capital deficiency of $30.5 million, alongside an accumulated deficit of $112.7 million. Management explicitly stated that substantial doubt exists regarding the company’s ability to continue as a going concern, citing inadequate working capital and reliance on related-party financing. The filing also reveals that the company’s insurance coverage has lapsed since early 2024 due to non-payment of premiums, exposing the business to uninsured liability risks.
Key figures
- Eps
- 0
- Revenue
- 627462
- Total Debt
- 36850622
- Cash Position
- 633
- Litigation Accrual
- 916000
- Shares Outstanding
- 669790294
- Unpaid Lease Payments
- 4481131
- Related Party Liabilities
- 29042615
Price after filing
Close on the filing date to close N calendar days later (from $0.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.